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Squamous cell carcinoma of the oral cavity evolves within a field of precancerized oral epithelium containing
keratinocytes at different stages of transformation. Following acquisition of additional genetic alterations, these
precancerous keratinocytes may become cancerous.
Persons with apparently successfully treated oral squamous cell carcinoma are at high risk of developing a new
carcinoma at, or close to the site of the treated tumour. This second carcinoma may have developed either from
malignant keratinocytes left behind at surgery (recurrence), or from transformed keratinocytes within the field of
precancerized epithelium from which the primary carcinoma had arisen (new carcinoma).
The cells of the new carcinoma may have genetic changes in common with the cells of the original carcinoma
because both are descended from a proliferating monoclone within the precancerized field; but if the new cancer
originates from a different clone, it may have a dissimilar genetic profile even if the original and the new carcinoma
are closely contiguous.
The purpose of this article is to review the pathobiology of oral squamous cell carcinoma in relation to fields of
precancerised oral epithelium.
Keywords: Field precancerisation, Oral squamous cell carcinomaIntroduction
Squamous cell carcinoma of the oral cavity constitutes
about ninety percent of all oral malignancies. It can af-
fect any site of the oral mucosa, but most commonly the
tongue and the floor of the mouth. Despite advances
in diagnostic techniques and improvement in treatment
modalities, the prognosis of oral squamous cell carcin-
oma (OSCC) remains poor, mainly owing to the high-
rate of local and regional recurrence and to the develop-
ment of new malignant changes within the original field
of precancerisation [1-7].
Most OSCCs develop within fields of precancerized
epithelium which contain keratinocytes at different sta-
ges of transformation. The persistence of such precance-
rized fields where there has previously been OSCC is the
reason for the high-rate of occurrence of new tumours
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reproduction in any medium, provided the orAlthough the literature almost invariably refers to a
field of epithelium containing genetically altered kera-
tinocytes at different stages of transformation as a field
of cancerization, we prefer to term such a field, a field
of precancerization. This is because only upon acqui-
sition of additional genetic alterations, will the initially
transformed precancerous keratinocytes become cancer-
ous giving rise to a carcinoma or to multiple carcinomas.
As long as a carcinoma has not become apparent in an
epithelial field containing genetically altered keratino-
cytes, the correct term of this field is a precancerized
epithelial field, and the term field of cancerization is
inappropriate.
The purpose of this article is to review the patho-
biological mechanisms that bring about the formation of
precancerized fields of epithelium from which OSCC
can arise.The biology of oral epithelium as it relates to OSCC
The oral epithelium is in a constant process of turnover.
Thin non-keratinized epithelia such as those of the epi-
thelium of the floor of the mouth and of the ventraltd. This is an Open Access article distributed under the terms of the Creative
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thick keratinized epithelia, such as those of the hard pal-
ate and the gingiva. This is because the rate of prolifera-
tion of basal keratinocytes is higher in non-keratinized
epithelium than in keratinized epithelium. The risk of
cytogenetic mutations and subsequent cancerous trans-
formation is greater in basal keratinocytes with a higher
rate of cell division than in those with a lower rate of cell
division, hence the greater risk in non-keratinized epi-
thelium [11,12].
Proliferation of cells occurs in the basal and parabasal
layers of the oral epithelium which are referred to as
the progenitor cell compartment. This progenitor cell
compartment comprises two functionally distinct popu-
lations of cells: a smaller population of tissue-specific
stem cells, and a larger population of transient-amplify-
ing cells [11-13]. The tissue-specific stem cells occupy a
specialized niche in relation to their neighbouring cells.
The stem cells contain the genomic information of the
oral epithelium, are undifferentiated but have the cap-
acity to differentiate. They divide infrequently, have the
capacity for unlimited self-renewal, maintain active
expression of telomerase and do not readily undergo
apoptosis [11,12,14-17].
The mitotic division of a tissue-specific stem cell gives
rise either to two daughter stem cells which remain in
the stem cell niche or to one daughter stem cell which
remains in the stem cell niche and to a second daughter
transit-amplifying cell that leaves the stem cell niche,
but remains in the progenitor compartment. Subse-
quently, the transit-amplifying cells undergo mitosis and
each gives rise either to two daughter transit-amplifying
cells which remain in the progenitor compartment, or to
two daughter cells which begin to differentiate. Those
daughter cells which exit the progenitor compartment
and differentiate into keratinocytes, begin the process of
maturation and gradually rise through the morphologic-
ally distinct cell layers of the epithelium, to the surface
where they are shed [12,14,18].
The origin of the OSCC precursor cell
OSCC arises by malignant transformation of a single
precursor cell which by clonal expansion gives rise to a
monoclonal cancer cell population. It appears that the
precursor cancer cells possess the capacity for relatively
unlimited self-renewal but have a limited rate of apop-
tosis with the outcome of longevity and the ability to ini-
tiate and sustain the ongoing growth of the cancerous
tissue [18-21].
The origin of the precursor cell which gives rise to
OSCC is uncertain. It is likely that it arises, as is the case
in other cancers, from a tissue-specific stem cell or its
progenitor cell, which has acquired epigenetic and/or
genetic alterations. However, it is also possible that theOSCC precursor cell may have arisen from a stem cell
which has acquired a precancerous phenotype during
embryogenesis and has then differentiated into a tissue-
specific cancer stem cell [14,17,22,23]. Another possi-
bility is that the OSCC precursor cell originates from a
mature keratinocyte which has undergone cytogenetic
alterations resulting in its dedifferentiation into the
analogue of an immature progenitor/stem cell which can
express the dysregulated intracellular pathways and trans-
cription factors of a tissue-specific cancer stem cell phe-
notype [14,18,24,25].
Cancer precursor cells, regardless of how they may have
arisen possess the capacity for self-renewal, and hence are
capable of initiating and sustaining growth of a cancer. It
is likely that the OSCC comprises a heterogeneous popu-
lation of cancer stem cells, cancerous transit-amplifying
cells and post-mitotic cancerous cells at different stages of
abnormal differentiation [14,18,24,25]. The cancer stem
cells constantly provide new cancerous transit-amplifying
cells which have a high proliferative rate, thus perpetuat-
ing the growth of the carcinoma. The transit-amplifying
cancerous cells exhibit uncontrolled cell proliferation and
prolonged survival and are the force behind tissue in-
vasion and destruction; but owing to their limited
capacity of cell renewal, they cannot alone sustain tumour
growth. The post-mitotic cancerous keratinocytes at dif-
ferent stages of differentiation have no proliferative cap-
acity [15,18,20,26].
Thus the overall growth of OSCC is brought about by
the multiplication of cells with a cancer stem cell pheno-
type and by the uncontrolled proliferation of monoclonal
cancerous transit-amplifying cells [18].
Field precancerization in the mouth
It has been proposed that OSCC starts with the trans-
formation of a limited number of normal keratinocytes.
This transformation may be brought about by epigenetic
and cytogenetic changes that affect cell cycle progres-
sion, DNA repair mechanisms, differentiation and apop-
tosis, all of which may be caused by random mutations,
by exposure to any one or more of a variety of bio-
logical, chemical or physiological carcinogenic agents, or
by errors in DNA repair processes. Accumulation of
additional genetic events in the transformed precancer-
ous keratinocytes may confer upon them a growth dom-
inance over the normal neighbouring cells, resulting in
their increased representation in the affected epithelium.
This creates a field of precancerized epithelium (Figure 1)
[8,14,17,23,27-30].
The altered keratinocytes in a field of precancerized
epithelium may be genetically similar if they have arisen
from a single transformed progenitor cell which under-
went clonal expansion and subsequent clonal divergence,
or may be genetically dissimilar if they have arisen from
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Figure 1 Schematic presentation of field precancerization in relation to OSCC. (Based on reference [30]).
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in the evolution of subclones of keratinocytes which
have had multiple episodes of cytogenetic and epigenetic
alterations. In both cases the transformed clones spread
laterally at the expense of the surrounding normal ke-
ratinocytes creating a field of precancerization. The size
of the field increases slowly at a rate determined by the
rate of cellular multiplication in that particular micro-
environment, and may reach several centimetres in dia-
meter [6,8,14,23].
Thus, a large number of genetically altered keratino-
cytes of similar or dissimilar clonal origin make up a
field of precancerized epithelium which clinically ap-
pears normal but microscopically may show epithelial
dysplasia, or in time may give rise to precancerous le-
sions (leukoplakia, erythroplakia) and can be discrete
from, or contiguous with other precancerized fields in
the affected anatomical site (Figure 1) [8,14].The genomic instability which brings about the initial
transformational events may confer upon the transfor-
med keratinocytes in the precancerized epithelial field a
phenotype which predisposes them to a heightened risk
of additional genetic mutations. Ultimately, this mutator
phenotype may drive the affected cells towards acquisition
of a complete set of genetic alterations of a cancerous
phenotype, characterized by progressive uncontrolled cel-
lular growth [8,9,14,23,31-36].
However, it has also been proposed that the initiating
events in the transformation of a normal keratinocyte to
a cancerous keratinocyte, as well as the genetic events
sustaining tumour growth, may be brought about by
local evolutionary natural selection rather than by the
mutator phenotype, thus promoting cytogenetic insta-
bility [37-39]. According to this concept, carcinogenesis
usually starts with a normal rate of mutation. Subsequent
repetitive rounds of mutations together with selection and
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lective growth advantage. This process does not necessi-
tate an increase in mutation rate (a mutator phenotype)
[37]. Indeed, in early transformational events associated
with the formation of a precancerized field, factors such as
population density of transformed cells rather than the
mutator phenotype of the cells may play an important role
[40]. Subsequently, environmental selection pressures act
on the genetically heterogeneous clonal cell population of
the precancerized field driving the evolution of subclones
of cells which are fitter with regard to survival and prolif-
eration, and consequently have a growth advantage over
normal neighbouring cells [39,41].
Field precancerization in relation to OSCC
The number and combination of genetic alterations
which are necessary and sufficient to initiate OSCC, and
the sequence in which such alterations occur, are
unknown. However, it is probable that evolutionary pro-
cesses will favour mutation of genes which allow dys-
regulation of the cell cycle checkpoints, thus promoting
increased cell proliferation. This will confer upon the
transformed cells a growth advantage [41].
The probability of progression of precancerous pro-
genitor keratinocytes to cancer cells varies in different
precancerized fields, and it is impossible with confidence
to distinguish histomorphologically or genetically be-
tween those keratinocytes that are destined to remain
stable and those that are destined to acquire a full can-
cerous phenotype [14].
Furthermore, although carcinomatous transformation
of normal progenitor keratinocytes is brought about by
well recognised cytogenetic alterations, currently there
are no reliable molecular or genetic predictors of carcin-
omatous transformation of precancerized keratinocytes
[14,42-45]. At present, high-grade epithelial dysplasia,
DNA aneuploidy and loss of heterozygosity at certain
defined chromosomal loci, are associated with a greater
risk of carcinomatous transformation [14,45-51].
In those fields of oral epithelium in which the pre-
cancerized keratinocytes are already committed to the
pathway of cancerization, progression to cancer may vary
from 6 months to 8 years. However, the factors which de-
termine the speed of the transformation are unknown
[14,46,48].
Once a carcinoma has evolved, the molecular diversity
of cancerous cells within a single tumour [52] drives the
evolution of subclones of cancerous cells via the process
of natural selection [53]. The cell population of each of
the subclones within the tumour microenvironment har-
bours distinct genetic profiles with specific biological
properties [53,54]. In response to environmental selec-
tion pressures such as hypoxia or metabolic stresses, the
intratumour genetic heterogeneity favours the evolutionand survival of subclones of cells which will than have a
growth advantage [55]. The multiple subclones occupy
distinct regional niches within the tumour microenvir-
onment [52] and may either compete with each other in
which case the dominant subclone will drive the process
of carcinogenesis or they may complement each other in
which case the subclones together will drive the process
of carcinogenesis (Figure 1) [53]. Common genetic alter-
ations found in all cancerous cells of the subclones are
probably the outcome of initial genetic events while less
common genetic alterations represent secondary genetic
events [52].
The existence of an epithelial field of precancerization
may explain several aspects of the pathobiological behav-
iour of OSCC. Firstly, it can explain why many cases of
OSCC arise from, or are closely contiguous with precan-
cerous lesions such as oral leukoplakia or erythroplakia;
secondly, it can explain why apparently normal-looking
epithelium surrounding OSCC harbours cells with gen-
etic alterations and/or cells with dysplasia. This may ac-
count for the high-rate of recurrence of OSCC despite
apparently successful excision. Lastly, the existence of an
epithelial field of precancerisation may also explain why
more than one OSCC not uncommonly may manifest
synchronously or metachronously, and may have similar
or dissimilar molecular profiles depending upon whether
they developed from subclones descended from a single
monoclone or from polyclones [14].Genomic instability as it relates to fields of
precancerization
The cellular genomic integrity of keratinocytes is main-
tained by various mechanisms including DNA monitor-
ing and repair, checkpoints that regulate the cell cycle
and genes that ensure the accurate replication and segre-
gation of chromosomes during mitosis. Malfunction of
these mechanisms may either bring about genomic in-
stability which is associated with an increased risk of ac-
quiring additional genetic alterations; or it may confer
upon the transformed keratinocytes growth advantage
over the normal neighbouring keratinocytes that can ul-
timately culminate in carcinoma [20,28,29,56-58].Defects in DNA repair mechanisms
Damage to DNA in keratinocytes may be caused by
many factors including spontaneous mutations, errors
in DNA replication brought about by misincorpora-
tion of nucleotides by DNA polymerases, or by a va-
riety of exogenous and endogenous mutagens [57,58].
If the damage to DNA affects critical genes and ex-
ceeds the cell’s repair capacity, the altered DNA may
propagate by cell division, promoting cell transforma-
tion and carcinogenesis.
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rects covalent alterations to DNA induced by chemical
mutagens [58], and by ultraviolet-induced helix–distor-
ting lesions of DNA [59]. Functional defects in NER
genes in keratinocytes bring about an accumulation of
mutations that are associated with an increased risk of
SCC, particularly of the skin [59].
Genetic or epigenetic inactivation of the DNA mis-
match repair mechanisms which normally function in
correcting DNA replication errors may result in the for-
mation of changes in the lengths of the repetitive
nucleotide sequences. This occurs mainly in DNA seg-
ments between genes (microsatellite sequences) and is a
specific type of genomic instability termed microsatellite
instability [57]. Microsatellite instability may also be
brought about by inherently error-prone DNA polymer-
ases which during DNA replication generate errors of a
magnitude that exceeds the normal capacity for cor-
rection by mismatch repair [60]. In turn, the mutated
microsatellite sequences may cause inactivation of tu-
mour suppressor genes [61]. Thus, as mutated repetitive
sequences can be found within coding regions of growth
regulatory genes, microsatellite instability can promote
mutagenesis [61].
While in hereditary cancers, mutations in DNA repair
genes are common, in sporadic non-hereditary cancers
mutations in DNA repair genes are infrequent, and if pre-
sent, probably represent late carcinogenic events [62]. For
example, molecular alterations in Fanconi anemia/BRCA
intracellular signalling pathways that regulate cellular re-
pair of DNA damage are a risk for OSCC [63]. OSCC in
association with Fanconi anemia occurs in a significantly
higher frequency and at a younger age than the oc-
currence of oral squamous cell carcinoma in the general
population. Functional inactivation of Fanconi anemia/
BRCA pathways are also observed in some cases of spor-
adic OSCC [63-65].Oncogenes and tumour suppressor genes
(anti-oncogenes)
In sporadic cancers, the genomic instability is charac-
terized by molecular alterations of oncogenes, of tumour
suppressor genes (anti-oncogenes), and/or of DNA check-
point control genes. Increased activity of oncogenes
results in excessive cell proliferation with consequent
increase in DNA damage. Tumour suppressor genes
function as anti-oncogenes regulating intracellular growth
signal pathways. DNA checkpoint control genes ultimately
induce cell death in response to DNA damage which
exceeds the repair capacity of the cells. This prevents
propagation of altered DNA to daughter cells. Some
tumour-suppressor genes (e.g. p53) are also involved
in arrest of the cell cycle and in apoptosis [62,66].Mutations in oncogenes conferring cellular self-suffi-
ciency in growth signals, or in tumour suppressor genes
resulting in dysfunctional anti-oncogenic activity, or mu-
tations in both, may induce deviations in DNA replica-
tion, leading to accumulation of DNA damage and
consequent genetic instability. This process is not suffi-
cient to induce a complete set of genomic alterations of
a cancerous phenotype, but can be an initiating event in
carcinogenesis, establishing a state of precancerization
[62,67]. Overexpression of numerous oncogenes includ-
ing epidermal growth factor and its ligand, transforming
growth factor-α, and loss of function of several tumour-
suppressor genes including TP53, TP16 and NOTCH1
have been implicated in the pathogenesis of OSCC
[66,68-70]. It appears that carcinomatous cells of squa-
mous cell carcinomas of the head and neck contain
more inactivating mutations in tumour suppressor ge-
nes (anti-oncogenes)than activating mutations in on-
cogenes [70].
Normally, excessive DNA damage will activate DNA
checkpoint control genes (e.g. p53), mediating apoptosis.
However, later in the chain of genetic events of carcino-
genesis, loss of function of DNA checkpoint control
genes owing to evolutionary selection pressures or to
carcinogen-induced mutations, or to sporadic muta-
tions, will enable the initially transformed cells to evade
apoptosis, and ultimately to acquire a cancerous pheno-
type [62].
Human papillomavirus (HPV)-negative squamous cell
carcinoma of the head and neck (HNSCC) is burdened
with more genetic alterations than HPV-positive HNSCC;
and HNSCC-associated with tobacco, is burdened with
more mutations than HNSCC not related to tobacco
use [70].
Chromosomal instability
Chromosomes of cancer cells are unstable [62,71], cha-
racterised by diverse chromosomal aberrations including
aneuploidy, deletions, translocations, amplifications and
are subject to abnormal mitoses [56-58,60-62]. Chro-
mosomal instability may be brought about by non-specific
chromosomal errors (aneuploidy), by specific mutations of
mitotic control genes, or by evolutionary selection pres-
sures imposed by the somatic environment. In turn, the
chromosomal errors impose selection pressures that
favour molecular alterations in mitotic checkpoint genes,
allowing the replication of cells with chromosomal alter-
ations. Had there not been loss of function of mitotic
checkpoint control genes, the cells harbouring chromo-
somal errors would have undergone apoptosis [71].
Large-scale genomic gains or losses may result in over-
expression of oncogenes or in loss of function of tumour
suppressor genes, thus promoting carcinogenesis [72].
The loss of heterozygosity which is a loss of paternal or
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suppressor genes occurs frequently in transformed kera-
tinocytes of potentially malignant oral lesions. Loss of
heterozygosity at specific chromosomal regions in these
keratinocytes (e.g. 3p, 9p, 17p, 13q, 18q) is associated with
progression of potentially malignant lesions to oral SCC
[14,46,47,50,68,72,73].
Aneuploidy involving chromosomes that have genes
governing mitosis destabilizes the karyotype, causing a
degree of chromosomal instability which is proportional
to the degree of aneuploidy [74]. The risk of potentially
malignant oral lesions progressing to OSCC is thus much
greater for those lesions manifesting aneuploidy than for
those with diploidy [14,51,75,76]. Indeed, it has been
reported that about 80% of OSCCs harbour DNA aneu-
ploidy [77], and that acquisition of aneuploidy is an early
genetic event in oral carcinogenesis [78].
It is not clear whether chromosomal instability is the
driving force of carcinogenesis or merely a by-product,
and whether it occurs as a consequence of the high rate
of mutations in specific genes maintaining the stability
of cellular genetic material; or whether these mutations
only evolve secondarily to the chromosomal instability
[71,79]. Nevertheless, it is accepted that the acquisition
of chromosomal instability is an early event in carcino-
genesis [80,81].
Summary
Most OSCCs develop in fields of precancerized epithe-
lium in which there is clonal expansion of phenotypically
normal but genetically altered keratinocytes. These ge-
netically unstable precancerous keratinocytes manifest
aneuploidy, gain or loss of chromosomal material, or al-
terations in the sequences of nucleotides. The genomic
instability favour further acquisition of genetic altera-
tions leading to growth superiority or inferiority of the
affected cells. The genetically advantaged cells may ul-
timately acquire a cancerous phenotype.
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